The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1252
A Low-Dose Doxycycline (Oracea) for Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A new once-daily, low-dose oral formulation of doxycycline monohydrate (Oracea – CollaGenex) has been approved by the FDA for treatment of inflammatory papules and pustules associated with rosacea in adults.

STANDARD TREATMENT —What role, if any, bacteria play in the etiology of rosacea is unknown, but both topical and oral antibacterials are often used to treat it.1 Oral antibiotics tend to be effective for treatment of papules, pustules, erythema and ocular inflammation, but not for telangiectasia, rhinophyma, or the flushing that generally occurs in this disorder. Prolonged courses (months or sometimes years), which are often needed, can lead to bacterial resistance.2

MECHANISM OF ACTION — The efficacy of tetracyclines such as doxycycline in rosacea may be due to their anti-angiogenic and anti-inflammatory properties, rather than an ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Low-Dose Doxycycline (Oracea) for Rosacea
Article code: 1252a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian